Intra-Cellular Therapies, Inc.
ITCI
Helyezés a részvények között
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Részvényárfolyam
$131.87
Utolsó szinkronizálás: 2025-04-02
Piaci kapitalizáció
$12.68B
Változás (1 nap)
0.00%
Változás (1 év)
0.00%
Ország
US
Kereskedés Intra-Cellular Therapies, Inc. (ITCI)
Kategória
Healthcare
Intra-Cellular Therapies, Inc. (ITCI) P/S aránya
P/S arány ekkor: October 2026 TTM: 20.63
Intra-Cellular Therapies, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 20.63. 2023 végén ez az arány 14.79 volt.
P/S arány története a(z) Intra-Cellular Therapies, Inc. esetén 2013 és 2026 között
P/S arány az év végén
| Év | P/S arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 20.63 | 63.10% |
| 2024 | 12.65 | -14.45% |
| 2023 | 14.79 | -25.98% |
| 2022 | 19.98 | -61.62% |
| 2021 | 52.05 | -47.59% |
| 2020 | 99.31 | -99.68% |
| 2019 | 31.24K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | 2.72K | 37.86% |
| 2016 | 1.97K | -90.69% |
| 2015 | 21.20K | 2,320.46% |
| 2014 | 875.93 | 827.98% |
| 2013 | 94.39 | 0.00% |
P/S arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/S arány | P/S arány különbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -65.79% |
IN
|
